CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. The Company's two key clinical development candidates are Seladelpar and Arhalofenate. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and the epidemic in nonalcoholic SteatoHepatitis. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. The Company's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.